[go: up one dir, main page]

BR9909529A - Paroxetine maleate - Google Patents

Paroxetine maleate

Info

Publication number
BR9909529A
BR9909529A BR9909529-7A BR9909529A BR9909529A BR 9909529 A BR9909529 A BR 9909529A BR 9909529 A BR9909529 A BR 9909529A BR 9909529 A BR9909529 A BR 9909529A
Authority
BR
Brazil
Prior art keywords
paroxetine maleate
paroxetine
maleate
depression
things
Prior art date
Application number
BR9909529-7A
Other languages
Portuguese (pt)
Inventor
Victor Witold Jacewicz
John Man
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807627.6A external-priority patent/GB9807627D0/en
Priority claimed from GBGB9823856.1A external-priority patent/GB9823856D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BR9909529A publication Critical patent/BR9909529A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MALEATO DE PAROXETINA'' Maleato de paroxetina e a sua preparação e uso no tratamento e prevenção de, entre outras coisas, a depressão."PAROXETINE MALEATE '' Paroxetine maleate and its preparation and use in the treatment and prevention of, among other things, depression.

BR9909529-7A 1998-04-09 1999-04-09 Paroxetine maleate BR9909529A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9807627.6A GB9807627D0 (en) 1998-04-09 1998-04-09 Novel compounds
GBGB9823856.1A GB9823856D0 (en) 1998-10-30 1998-10-30 Novel compound
PCT/GB1999/001106 WO1999052901A1 (en) 1998-04-09 1999-04-09 Paroxetine maleate

Publications (1)

Publication Number Publication Date
BR9909529A true BR9909529A (en) 2000-12-12

Family

ID=26313449

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909529-7A BR9909529A (en) 1998-04-09 1999-04-09 Paroxetine maleate

Country Status (18)

Country Link
EP (1) EP1073652A1 (en)
JP (1) JP2002511466A (en)
KR (1) KR20010042552A (en)
CN (1) CN1305474A (en)
AP (1) AP2000001950A0 (en)
AU (1) AU3433499A (en)
BG (1) BG104914A (en)
BR (1) BR9909529A (en)
CA (1) CA2327450A1 (en)
EA (1) EA200001050A1 (en)
HU (1) HUP0103651A3 (en)
ID (1) ID26879A (en)
IL (1) IL138920A0 (en)
NO (1) NO20005037L (en)
PL (1) PL343378A1 (en)
SK (1) SK15032000A3 (en)
TR (1) TR200002939T2 (en)
WO (1) WO1999052901A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
CH689805A8 (en) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Paroxetine methanesulfonate, process for its preparation and pharmaceutical compositions containing it.
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
NL1017421C2 (en) 2001-02-21 2002-01-15 Synthon Bv Process for the production of paroxetine.
KR100672184B1 (en) 2004-09-21 2007-01-19 주식회사종근당 Choline or Choline Derivative Salts of Paroxetine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
SK283394B6 (en) * 1997-06-10 2003-07-01 Synthon B. V. 4-phenylpiperidine compounds and its pharmaceutically acceptable salts, process for their preparation, medicament containing them and their use

Also Published As

Publication number Publication date
EP1073652A1 (en) 2001-02-07
AP2000001950A0 (en) 2000-12-31
WO1999052901A1 (en) 1999-10-21
AU3433499A (en) 1999-11-01
PL343378A1 (en) 2001-08-13
JP2002511466A (en) 2002-04-16
NO20005037D0 (en) 2000-10-06
HUP0103651A3 (en) 2002-12-28
NO20005037L (en) 2000-12-05
BG104914A (en) 2001-10-31
CN1305474A (en) 2001-07-25
HUP0103651A2 (en) 2002-08-28
EA200001050A1 (en) 2001-04-23
TR200002939T2 (en) 2001-02-21
ID26879A (en) 2001-02-15
SK15032000A3 (en) 2001-04-09
CA2327450A1 (en) 1999-10-21
KR20010042552A (en) 2001-05-25
IL138920A0 (en) 2001-11-25

Similar Documents

Publication Publication Date Title
BR9916857A (en) 4 heteroaryl diarylamines
BR9708400A (en) Composition, preparation and use
NL300295I1 (en) 3,3-Diarylpropylamines, their use and preparation
GB2365772A (en) Factor
BR9612111A (en) Poli (9'9- spirobisfluorenes), their preparation and use
FI955315A0 (en) HIV protease inhibitors useful in the treatment of AIDS
BR9911682A (en) Paroxetine methane sulfonate
NO964306D0 (en) Lignin blend, preparation and use thereof
DK0832104T3 (en) Dolastatin derivatives, their preparation and use
BG105256A (en) Muscarinic agonists and antagonists
IT1304008B1 (en) DEVICE FOR THE ELIMINATION OF RATS AND SIMILAR.
BR9506389B1 (en) silicon, and dietary, cosmetic and therapeutic composition.
DE58902899D1 (en) 2 ', 3'-DIDEOXYPURINNUCLEOSIDE / PURINNUCLEOSIDE-PHOSPHORYLASE INHIBITOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR.
BR9909529A (en) Paroxetine maleate
PT929299E (en) 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINS AND 2-AMINOCYCLOHEPTA ¬B | BENZOFURANOS SUBSTITUIDOS
PT811593E (en) INSECTICID AND ACARICID AGENTS 1,4-DIARY-2-FLUOR-2-BUTENE
MD970269A (en) Clavulanates
ES2152315T3 (en) XAMONELINE TARTRATO.
NO982942D0 (en) Blood compatible and bactericidal block copolymer
MD980129A (en) Antiherpetic remedy
AU2001296780A1 (en) 48120, 23479, and 46689, novel human hydrolases and uses thereof
NO20021429L (en) 1,4-dioxacycloalkan-2-one and 1,4-dioxacycloalken-2-one
ZA9710515B (en) N-(imidazolybutyl) benezenesulphonamide derivatives, their preparation and their application in therapeutics.
ZA989312B (en) Novel pharmaceutically active compounds, their preparation and use.
DK0828740T3 (en) 2-Azabicyclo [2.2.1] heptane derivatives, their preparation and use

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]